Novo Nordisk A/S
NVO
$122.71
-$0.04-0.03%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 43.94% | 38.99% | 34.29% | 21.26% | 12.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.94% | 38.99% | 34.29% | 21.26% | 12.09% |
| Cost of Revenue | 27.39% | 45.47% | 32.11% | 12.96% | 18.28% |
| Gross Profit | 47.37% | 37.77% | 34.67% | 22.89% | 10.89% |
| SG&A Expenses | 29.72% | 20.37% | 32.96% | 15.45% | 5.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 99.27% | -76.12% | 110.27% | 91.96% | -222.38% |
| Total Operating Expenses | 30.95% | 35.17% | 35.69% | 18.35% | 12.58% |
| Operating Income | 65.95% | 43.78% | 32.56% | 24.73% | 11.26% |
| Income Before Tax | 77.91% | 67.82% | 47.38% | 31.83% | 11.17% |
| Income Tax Expenses | 118.26% | 66.04% | 41.65% | 26.76% | 9.58% |
| Earnings from Continuing Operations | 69.83% | 68.26% | 48.88% | 33.16% | 11.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 69.83% | 68.26% | 48.88% | 33.16% | 11.49% |
| EBIT | 65.95% | 43.78% | 32.56% | 24.73% | 11.26% |
| EBITDA | 62.45% | 42.83% | 32.82% | 22.72% | 17.33% |
| EPS Basic | 71.46% | 70.02% | 50.49% | 34.74% | 12.98% |
| Normalized Basic EPS | 74.20% | 69.56% | 48.96% | 33.41% | 18.33% |
| EPS Diluted | 71.41% | 70.09% | 50.30% | 34.80% | 13.01% |
| Normalized Diluted EPS | 74.26% | 69.62% | 49.02% | 33.41% | 18.27% |
| Average Basic Shares Outstanding | -0.96% | -1.02% | -1.06% | -1.18% | -1.31% |
| Average Diluted Shares Outstanding | -1.00% | -1.06% | -1.09% | -1.17% | -1.27% |
| Dividend Per Share | 65.07% | -- | 44.08% | -- | 5.52% |
| Payout Ratio | -- | -0.10% | -- | -0.16% | -- |
